(102CT2018) a Multi-Center Phase II Study of AUY922 in Patients with Stage IV Advanced Non-Small Cell Lung Cancer with Driver Molecular Alterations Other Than Sensitive EGFR Mutation, Who Have Progressed after One Line of Systemic Therapy (II)

2014-11-012024-05-18https://scholars.lib.ntu.edu.tw/handle/123456789/713559(102CT2018) a Multi-Center Phase II Study of AUY922 in Patients with Stage IV Advanced Non-Small Cell Lung Cancer with Driver Molecular Alterations Other Than Sensitive EGFR Mutation, Who Have Progressed after One Line of Systemic Therapy (II)